Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. (Q54153850)

25 May 2018

title

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. (English)

1 reference

25 May 2018

1 reference

2

1 reference

25 May 2018

Bo Ahrén

series ordinal

1

object named as

Ahrén B

1 reference

25 May 2018

author name string

Mårtensson H

series ordinal

3

1 reference

25 May 2018

Balkan B

series ordinal

4

1 reference

25 May 2018

language of work or name

English

0 references

publication date

1 September 2000

1 reference

25 May 2018

European Journal of Pharmacology

published in

1 reference

25 May 2018

volume

404

1 reference

25 May 2018

issue

1-2

1 reference

25 May 2018

page(s)

239-245

1 reference

25 May 2018

Glucagon-like peptide-1 (GLP-1): a gut hormone of potential interest in the treatment of diabetes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Effects of peptide HI on basal and stimulated insulin and glucagon secretion in the mouse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Glucagon-like peptide-1 7-36: a physiological incretin in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Is glucagon-like peptide 1 an incretin hormone?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Stimulation of truncated glucagon-like peptide-1 release from the isolated perfused canine ileum by glucose absorption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0014-2999%2800%2900600-2

10.1016/S0014-2999(00)00600-2

7 January 2021

Identifiers

DOI

1 reference

25 May 2018

PubMed ID

10980284

1 reference

25 May 2018